Literature DB >> 29033047

Effect of Hemodialysis on Levels of High-Sensitivity Cardiac Troponin T.

Michael Chen1, Howard Gerson2, Shaun Eintracht2, Sharon J Nessim3, Elizabeth MacNamara2.   

Abstract

Cardiac troponin (cTn) is essential for the diagnosis of an acute coronary syndrome (ACS). However, in end-stage renal disease (ESRD) baseline cTn levels are often elevated, and it is unknown whether the hemodialysis (HD) procedure affects cTn levels. This leaves clinicians unsure of how to interpret cTn in HD patients with cardiac ischemia. We therefore sought to determine if plasma levels of high-sensitivity cardiac troponin T (hs-cTnT) vary during or after HD treatment. We prospectively enrolled 10 chronic HD patients who were admitted to our institution. All participants were receiving thrice weekly HD before admission and were medically stable. Those admitted for ACS or to critical care units were excluded. Baseline hs-cTnT was measured immediately before HD. For the subsequent 6 hours, hs-cTnT was measured every 2 hours and every 3 hours thereafter for a total collection period of 24 hours. A significant decline in mean hs-cTnT was noted with HD. During HD (2 hours after HD initiation), hs-cTnT decreased by 10.7% (confidence interval 5% to 17%). Immediately after HD (4 hours after HD initiation), a decline of 12% (confidence interval 5% to 19%) was observed. Thereafter hs-cTnT began to rise. Hs-cTnT levels returned to baseline by 11 hours after HD completion and remained stable for the reminder of the study. In conclusion, HD induces a short-lived negative bias in hs-cTnT. When measured for investigation of ACS, hs-cTnT concentration should be interpreted with respect to time of dialysis and specimen collection.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29033047     DOI: 10.1016/j.amjcard.2017.08.026

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

Review 1.  The Confounding Effects of Non-cardiac Pathologies on the Interpretation of Cardiac Biomarkers.

Authors:  Marin Nishimura; Alison Brann; Kay-Won Chang; Alan S Maisel
Journal:  Curr Heart Fail Rep       Date:  2018-08

2.  High-sensitive troponin T increase after hemodialysis is associated with left ventricular global longitudinal strain and ultrafiltration rate.

Authors:  Serkan Ünlü; Asife Şahinarslan; Burak Sezenöz; Orhan Mecit Uludağ; Gökhan Gökalp; Özden Seçkin; Selim Turgay Arınsoy; Özlem Gülbahar; Nuri Bülent Boyacı
Journal:  Cardiol J       Date:  2018-10-19       Impact factor: 2.737

3.  Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia.

Authors:  Tobias Dittrich; Axel Benner; Christoph Kimmich; Fabian Aus dem Siepen; Kaya Veelken; Arnt V Kristen; Tilmann Bochtler; Hugo A Katus; Carsten Müller-Tidow; Ute Hegenbart; Stefan O Schönland
Journal:  Haematologica       Date:  2019-01-17       Impact factor: 9.941

4.  Variability of high-sensitivity cardiac troponin T and I in asymptomatic patients receiving hemodialysis.

Authors:  Wanwarang Wongcharoen; Teetad Chombandit; Arintaya Phrommintikul; Kajohnsak Noppakun
Journal:  Sci Rep       Date:  2021-08-30       Impact factor: 4.379

5.  Monthly measurement of high-sensitivity cardiac troponins T and creatine kinase in asymptomatic chronic hemodialysis patients: A one-year prospective study.

Authors:  Stéphane Gremaud; Benoît Fellay; Ould Maouloud Hemett; Jean-Luc Magnin; Eric Descombes
Journal:  Hemodial Int       Date:  2021-12-13       Impact factor: 1.543

6.  Variation of High-Sensitivity Troponin T Results in Patients Undergoing Continuous Renal Replacement Therapy.

Authors:  Vikas Srinivasan Sridhar; Michael Chen; Howard Gerson; Elizabeth MacNamara; Sharon J Nessim
Journal:  Can J Kidney Health Dis       Date:  2019-02-15

7.  Troponin Levels Relate to CRP Concentrations in Patients With NAFLD on Maintenance Haemodialysis: A Retrospective Study.

Authors:  Domenico Capone; Mauro Vinciguerra; Annalisa Ragosta; Vincenzo Citro; Giovanni Tarantino
Journal:  Adv Ther       Date:  2020-06-08       Impact factor: 3.845

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.